Despite the lack of evidence that the two direct substrates of GCase accumulate in GBA carriers or in PD-GBA patients, no systematic studies have been performed to determine whether levels of other GSLs in the same metabolic pathway might be altered, or whether levels of other brain lipids change in PD-GBA. Here, GBA1 is linked to Parkinson disease.